adl5859
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00993863)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Delta opioid receptorAGONIST
OPRD1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- adl5859
- adl5859
- adl5859
- adl5859
- adl 5859
- adl-5859
- n,n-diethyl-4-(5-hydroxyspiro(chromene-2,4'-piperidine)-4-yl)benzamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00979953 | Phase 2 | Oct 1, 2009 | Cubist, Pfizer |
| NCT00603265 | Phase 2 | Nov 1, 2007 | Cubist |
| NCT00626275 | Phase 2 | Oct 1, 2007 | Cubist |
| NCT00993863 | Phase 2 | Jun 1, 2007 | Cubist |
Showing 4 of 4 trials
Page 1 / 1